D-Chiro-Inositol Combined with Metformin
Phase 3Small molecule
D-Chiro-Inositol Combined with Metformin is one of 44 small molecule programs targeting Insulin resistance. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
43
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
66 competitors in Insulin Resistance
#DrugCompanyPhaseTrials
1Avandia
Jazz PharmaceuticalsApproved
Glucophage
EMD SeronoApproved
Crestor
AstraZenecaApproved
Rozerem
TakedaApproved
Victoza
Novo NordiskApproved
Sovaldi
GileadApproved
Calciferol
Jazz PharmaceuticalsApproved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Tradjenta
Boehringer IngelheimApproved
Starlix
NovartisApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Insulin resistance1 trial
Effects of D-Chiro-Inositol Combined with Metformin on Insulin Resistance in People with Overweight or Obesity and T2DM
Active, not recruiting·—·Phase 4·NCT06860841·16 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- CCampus Bio-Medico University